Ionis Halves Tryngolza Sales Guidance as Slow Launch Overshadows a Strong Quarter

Ionis Pharmaceuticals cut its full-year Tryngolza sales guidance to about $50 million from $100 million to $110 million, citing a slower launch ramp.

Tryngolza (olezarsen) treats severe hypertriglyceridemia, very high blood fats that can trigger pancreatitis.

Its United States sales were $9 million in the third quarter. Sales were $32 million a year earlier.

Ionis cited a more gradual launch ramp than anticipated. It is establishing a new treatment paradigm for people with sHTG.

The quarter itself beat expectations on revenue. Total revenue rose to $243 million from $157 million a year earlier.

Ionis put the increase at 55%. Commercial growth and partnership revenue drove it.

The Zacks Consensus Estimate for revenue was $178.93 million. Reported revenue therefore beat that estimate by 35.8%, a calculation.

The reported GAAP loss was $110 million, or $0.66 a share. That compares with a $129 million loss, or $0.80, a year earlier.

Zacks put its Consensus Estimate for the loss at $1.00 a share. The GAAP loss was therefore 34.0% narrower than that estimate, a calculation.

Shares fell about 27% in intraday trading on Monday. The snapshot is as of 11:33 a.m. ET, from Friday's $39.42 close.

That move is intraday only, not a settled reaction. Monday's closing price is the first settled verdict.

Barron's reported the shares were heading for their worst single-day percentage drop since May 26, 2016, according to Dow Jones Market Data.

The plunge deepened an already steep year. The shares were down roughly 63% this year, by the same Dow Jones measure.

One guide cut, four reaffirmed

Ionis reaffirmed full-year total revenue guidance of $875 million to $900 million. It also reaffirmed its operating loss and cash guidance.

The reaffirmed operating loss guide is $425 million to $475 million, on a non-GAAP basis. Cash and short-term investments are still guided above $1.6 billion.

"While initial sales progress has been more gradual than anticipated, we are encouraged by the underlying launch fundamentals," Chief Executive Brett P. Monia said.

He said the company had identified clear opportunities to improve performance. No timetable or quantified target accompanied that pledge.

"We are lowering our 2026 TRYNGOLZA product sales guidance to reflect a more gradual ramp than we anticipated," Chief Financial Officer Elizabeth L. Hougen said.

She still cited multi-billion-dollar peak sales potential for the drug. That confidence now rests on a much smaller 2026 base.

The new guide implies fourth-quarter Tryngolza sales of about $9 million. That is a calculation: nine-month sales were $41 million against a roughly $50 million guide.

The cut is 50.0% against the old guide's low end, a calculation. Against the old midpoint, it is 52.4%, also a calculation.

Dawnzera carried the commercial quarter

Dawnzera (donidalorsen) prevents attacks of hereditary angioedema, a swelling disorder. Its United States sales were $37 million in the quarter.

Dawnzera remains on track for full-year sales of $110 million to $120 million. Nine-month sales were $79 million.

Total product sales were $48 million in the quarter. Commercial revenue rose 18% to $136 million.

Zanvastro (zilganersen) aims to slow the progression of Alexander disease. It recorded its first sales, $2 million, in the quarter.

Its launch is underway, with the first patients dosed commercially. It is the first approved medicine for Alexander disease.

Royalty revenue was $81 million in the quarter. Spinraza, for spinal muscular atrophy, supplied $69 million of royalties.

Wainua added $7 million of royalties and other royalties added $5 million. Those are royalty payments to Ionis, not Ionis product sales.

Partner sales of Spinraza rose 23% to $461 million globally. Wainua partner global sales were $68 million in the quarter.

Losses narrowed on both bases

The GAAP operating loss narrowed to $130 million from $160 million. The non-GAAP operating loss narrowed to $87 million from $129 million.

Research and development revenue jumped to $107 million from $41 million. Collaborative agreement revenue supplied $103 million of it, against $31 million.

The revenue beat was therefore driven mainly by partnership revenue. Product sales alone were $48 million of the $243 million total.

Selling, general and administrative costs rose to $154 million from $97 million. That rise works out to 58.8%, a calculation, on launch spending.

Operating expenses were $373 million on a GAAP basis. They were $330 million excluding equity-award compensation of $43 million.

The non-GAAP net loss was $67 million, against $98 million a year earlier. Ionis excludes equity compensation from its non-GAAP figures.

Cash, cash equivalents and short-term investments were $1.88 billion at September 30. That compares with $2.68 billion at the end of 2025.

Ionis repaid its 0% convertible notes on April 1, 2026. Operations also consumed cash during the year.

Pipeline news cut both ways

Europe gave Tryngolza a boost even as the guide fell. A European committee gave a positive opinion for severe hypertriglyceridemia.

A final European approval decision is expected in the fourth quarter. Approval would open the sHTG market across Europe.

A partnered heart study missed its main goal. Eplontersen missed the CARDIO-TTRansform primary composite endpoint in the overall population.

It showed nominal significance in the pre-specified monotherapy population. The safety and tolerability profile was favorable, Ionis said.

Two other partnered studies met their primary endpoints. Sefaxersen succeeded in kidney disease and ulefnersen in a form of ALS.

Hibsago, for chronic hepatitis B, has approvals in three countries. The United States, Japan and Canada have all approved it.

What remains unknown

What remains unknown starts with the settled verdict. The intraday plunge is known; Monday's closing price is not.

Whether the Tryngolza ramp speeds up is also unknown. Management named opportunities to improve, without quantifying them.

The European decision's outcome is unknown as well. A final sHTG approval decision is expected this quarter.

Whether peak-sales confidence survives a halved guide is untested. Only later quarters can show the ramp Ionis promises.

The fourth quarter tests the new guide

What to watch: fourth-quarter Tryngolza sales against the implied roughly $9 million pace. That pace is what the new guide requires.

The European sHTG decision is the second test. It is expected before the year ends.

Dawnzera's full-year landing is the third. It must reach $110 million to $120 million to match guidance.